Cannabis and Medication Interactions: What Your Doctor Won't Tell You

The Conversation That Isn’t Happening

Here’s a startling number: according to a 2019 Gallup poll, roughly 12% of American adults reported using cannabis. Meanwhile, nearly 66% of all American adults take at least one prescription medication [Georgetown University Health Policy Institute, 2019]. The overlap between these two groups is enormous—and growing every year as both cannabis legalization and prescription drug use expand.

Yet when was the last time your doctor proactively asked about your cannabis use and explained how it might interact with your medications? For most people, the answer is never.

This isn’t necessarily because your doctor doesn’t care. Many physicians received little to no training on the endocannabinoid system during medical school, and the federal scheduling of cannabis has made robust clinical research frustratingly difficult [Evanoff et al., 2017]. The result is a knowledge gap that leaves millions of people navigating a potentially significant pharmacological interaction with almost no guidance.

This article won’t replace a conversation with your healthcare provider—and I’ll encourage you to have that conversation throughout. What it will do is arm you with the science you need to ask the right questions, understand the real risks, and make more informed decisions about your wellness routine. We’ll explore how cannabis compounds are processed by your body, which medication classes deserve the most caution, and what practical steps you can take to stay safe.

Important disclaimer: This article is for educational purposes only. It is not medical advice. Never start, stop, or change any medication without consulting your doctor or pharmacist. If you use cannabis alongside prescription medications, please discuss this openly with your healthcare team.

The Science Explained

How Your Liver Processes (Almost) Everything

To understand cannabis-drug interactions, you first need to understand the body’s chemical processing plant: your liver.

Think of your liver as an incredibly sophisticated recycling center. When you consume almost any substance—a medication, a cup of coffee, a cannabis edible—it eventually arrives at the liver, where a family of enzymes breaks it down into smaller molecules your body can use or eliminate. This process is called metabolism, and the enzyme family doing most of the heavy lifting is called cytochrome P450 (often abbreviated as CYP450).

The CYP450 system isn’t just one enzyme—it’s a whole family of them, each with a specific job. The ones most relevant to cannabis interactions include:

• CYP3A4 — metabolizes roughly 50% of all pharmaceutical drugs [Zanger & Schwab, 2013]
• CYP2C9 — processes many anti-inflammatory drugs, blood thinners, and some antidepressants
• CYP2C19 — handles certain antidepressants, anti-anxiety medications, and proton pump inhibitors
• CYP1A2 — metabolizes caffeine, some antipsychotics, and melatonin
• CYP2D6 — processes many opioids, antidepressants, and beta-blockers

Now here’s where cannabis enters the picture. Both THC and CBD—the two most abundant cannabinoids—are metabolized by these same CYP450 enzymes. But they don’t just use these enzymes; they can also inhibit or compete with them, fundamentally altering how your body processes other drugs [Nasrin et al., 2021].

Imagine a two-lane highway where cars (your medications) travel at a predictable speed toward their destination (being broken down and eliminated). Now imagine CBD pulls onto that same highway and starts driving slowly in both lanes. The other cars—your medications—pile up behind it. They can’t get through at their normal rate. The result? Higher-than-expected levels of those medications circulating in your blood for longer than intended.

This is called enzyme inhibition, and it’s the single most important mechanism behind cannabis-drug interactions.

What the Research Shows

CBD: The Bigger Concern

Somewhat counterintuitively, CBD appears to be a more significant concern for drug interactions than THC in many cases. Research has shown that CBD is a potent inhibitor of several CYP450 enzymes, particularly CYP3A4 and CYP2C19 [Nasrin et al., 2021].

The most well-documented example comes from epilepsy research. When the FDA-approved CBD medication Epidiolex was studied in clinical trials, researchers found that CBD significantly increased blood levels of clobazam (a benzodiazepine used alongside Epidiolex for seizures) by inhibiting CYP2C19. Some patients experienced increased sedation and required dose adjustments [Geffrey et al., 2015].

This finding has been replicated and expanded. A comprehensive 2020 review in Clinical Pharmacology & Therapeutics identified CBD as a clinically relevant inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP1A2, concluding that “CBD has the potential to interact with many commonly used pharmaceuticals” [Bansal et al., 2020].

THC: A Different Profile

THC also interacts with CYP450 enzymes, but its inhibitory effects appear to be somewhat less potent than CBD’s at typical consumption levels [Nasrin et al., 2021]. However, THC introduces a different set of interaction concerns:

• Additive sedation: THC may compound the sedating effects of benzodiazepines, opioids, antihistamines, and certain antidepressants [Antoniou et al., 2020]
• Cardiovascular effects: THC can temporarily increase heart rate and affect blood pressure, which may interact with blood pressure medications and cardiac drugs [Page et al., 2020]
• CNS effects: THC’s psychoactive properties may interact unpredictably with psychiatric medications, including antipsychotics and mood stabilizers [Antoniou et al., 2020]

The Dose Factor

One critical nuance the research highlights: dose matters enormously. A person taking 1,000+ mg of CBD daily for epilepsy faces a very different interaction risk than someone using a 25 mg CBD gummy for relaxation. Many of the most dramatic interaction findings come from high-dose clinical contexts [Bansal et al., 2020].

That said, even moderate doses of CBD (50-150 mg) have shown measurable effects on enzyme activity in some studies, so lower doses don’t mean zero risk [Nasrin et al., 2021].

Medication Classes That Deserve Extra Caution

Based on the current evidence, here are the medication categories where cannabis interactions are most concerning:

The blood thinner warfarin deserves special emphasis. Multiple case reports have documented significant increases in INR (a measure of blood clotting time) when patients added CBD to their warfarin regimen, sometimes to dangerous levels [Grayson et al., 2018]. If you take warfarin and use any cannabis product—especially CBD—this is a conversation you must have with your doctor.

Beyond the Liver: Other Interaction Mechanisms

Enzyme inhibition is the most studied mechanism, but it’s not the only way cannabis can interact with medications:

Protein binding competition: Both THC and CBD bind heavily to plasma proteins in the blood. Many medications also rely on protein binding for transport. When cannabis compounds compete for binding sites, it can temporarily increase the “free” (active) concentration of medications [Lucas et al., 2018].

Receptor-level interactions: Cannabis compounds interact with the endocannabinoid system, serotonin receptors, GABA receptors, and others. Medications targeting these same receptor systems—like antidepressants, anti-anxiety drugs, and antipsychotics—may produce additive, synergistic, or even opposing effects [Antoniou et al., 2020].

Gastrointestinal effects: Cannabis can affect gut motility and gastric emptying time, which may alter the absorption rate of oral medications [McCallum et al., 1999].

Practical Implications

Connecting to Your Cannabis Experience

If you’re exploring cannabis for wellness, understanding these interactions helps you make smarter choices—not just about medications, but about which cannabis products and consumption methods to consider.

For instance, if you’re someone who takes a daily medication metabolized by CYP3A4, you might want to be particularly cautious with high-dose CBD products. On the other hand, a low-THC, terpene-rich product from the Balancing High family—which tends to have gentler, more moderate effects—might be a more conservative starting point worth discussing with your doctor.

Similarly, if you’re concerned about additive sedation with a medication, the Uplifting High or Energetic High families, characterized by terpenes like limonene and terpinolene, may produce a different experience profile than the deeply relaxing myrcene-dominant strains in the Relaxing High family. This doesn’t eliminate the pharmacological interaction, but understanding the terpene profile gives you more vocabulary for discussing your experience with a healthcare provider.

Actionable Steps You Can Take Today

1. Make a complete list of every medication, supplement, and cannabis product you use—including doses and frequency. Bring this to your next medical appointment.

2. Ask your pharmacist. Pharmacists are often more knowledgeable about drug interactions than physicians and are typically more accessible. Many will discuss cannabis interactions openly if you ask.

3. Check the enzyme pathway of your medications. Resources like the FDA drug label (available at DailyMed.nlm.nih.gov) list which CYP450 enzymes metabolize each drug. If you see CYP3A4, CYP2C19, or CYP2C9 listed, that’s a flag to investigate further.

4. Start low, go slow—especially with CBD products alongside medications. If your doctor approves concurrent use, begin with the lowest effective dose and monitor for any changes in how you feel on your medications.

5. Watch for warning signs. Increased side effects from your medications (more drowsiness, dizziness, bleeding, or mood changes) after adding cannabis could indicate an interaction. Report these to your healthcare provider promptly.

6. Time your doses thoughtfully. While this won’t eliminate enzyme-level interactions, some clinicians suggest separating cannabis and medication doses by several hours to reduce peak-level competition. Ask your doctor if this approach makes sense for your situation.

7. Be especially cautious with edibles and high-dose CBD oils. These pass directly through the liver (first-pass metabolism), maximizing the opportunity for enzyme interactions. Inhaled cannabis bypasses first-pass metabolism and may present a somewhat different interaction profile, though interactions can still occur [Huestis, 2007].

Key Takeaways

• CBD is often a bigger concern than THC for drug interactions because it potently inhibits several liver enzymes (CYP3A4, CYP2C19, CYP2C9) responsible for metabolizing many common medications [Nasrin et al., 2021].

• Blood thinners (especially warfarin), benzodiazepines, opioids, antidepressants, and immunosuppressants are among the medication classes with the most significant interaction potential with cannabis compounds.

• Dose matters enormously—high-dose CBD products carry substantially more interaction risk than low-dose products, but even moderate doses may have measurable effects on drug metabolism.

• Your pharmacist is your best ally. They’re trained in drug interactions and can often provide more specific guidance than a general practitioner on this topic.

• Having an honest conversation with your healthcare team about your cannabis use isn’t just recommended—for anyone on prescription medications, it’s essential for your safety.

FAQs

Does smoking cannabis cause fewer drug interactions than edibles?

Inhaled cannabis (smoking or vaping) bypasses first-pass liver metabolism, meaning the cannabinoids reach your bloodstream before being processed by liver enzymes [Huestis, 2007]. This may reduce—but does not eliminate—enzyme-level interactions. THC and CBD still reach the liver eventually through circulation, and receptor-level interactions (like additive sedation) occur regardless of consumption method.

Is CBD safe to take with antidepressants?

There isn’t a simple yes or no answer. Many common antidepressants (SSRIs like sertraline and citalopram) are metabolized by CYP enzymes that CBD can inhibit, potentially raising drug levels [Bansal et al., 2020]. Some people use CBD alongside antidepressants without noticeable issues, but this should always be done under medical supervision with appropriate monitoring. Never adjust your antidepressant dose on your own.

Will a small amount of THC interact with my medications?

Even small amounts of THC can produce additive effects with sedating medications or affect cardiovascular parameters in people taking heart medications [Antoniou et al., 2020]. However, the enzyme inhibition effects of THC appear less potent than CBD’s at typical recreational or wellness doses. The risk depends heavily on which medications you take, your individual metabolism, and how much THC you consume. When in doubt, consult your pharmacist.

Are there any medications that are completely safe to combine with cannabis?

No blanket statement of safety can be made for any medication-cannabis combination. Even over-the-counter medications like ibuprofen and acetaminophen share metabolic pathways with cannabinoids. That said, the clinical significance of interactions varies enormously—some are theoretical concerns while others are well-documented risks. A pharmacist can help you assess your specific medication profile.

Sources

Antoniou, T., Bodkin, J., & Ho, J.M. (2020). Drug interactions with cannabinoids. Canadian Medical Association Journal, 192(9), E206. https://doi.org/10.1503/cmaj.191097

Bansal, S., Maharao, N., Paine, M.F., & Unadkat, J.D. (2020). Predicting the potential for cannabidiol to precipitate pharmacokinetic drug interactions with small molecule oncology drugs. Drug Metabolism and Disposition, 48(10), 996–1005. https://doi.org/10.1124/dmd.120.000073

Caicedo, D.A., Pérez-Mañá, C., Farré, M., & Papaseit, E. (2025). An overview of the potential for pharmacokinetic interactions between drugs and cannabis products in humans. Pharmaceutics, 17(3), 319. https://doi.org/10.3390/pharmaceutics17030319

Evanoff, A.B., Quan, T., Dufault, C., Awad, M., & Bierut, L.J. (2017). Physicians-in-training are not prepared to prescribe medical marijuana. Drug and Alcohol Dependence, 180, 151–155. https://doi.org/10.1016/j.drugalcdep.2017.08.010

Geffrey, A.L., Pollack, S.F., Bruno, P.L., & Thiele, E.A. (2015). Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia, 56(8), 1246–1251. https://doi.org/10.1111/epi.13060

Grayson, L., Vines, B., Nichol, K., & Szaflarski, J.P. (2018). An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports, 9, 10–11. https://doi.org/10.1016/j.ebcr.2017.10.001

Hasanpoor, A., Akaberi, M., Kesharwani, P., Sobhani, Z., & Sahebkar, A. (2024). Drug interactions with Cannabis sativa: Mechanisms and clinical implication. Toxicologie Analytique et Clinique, 36, 131–145. https://doi.org/10.1016/j.toxac.2023.10.004

Huestis, M.A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804. https://doi.org/10.1002/cbdv.200790152

Lucas, C.J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology, 84(11), 2477–2482. https://doi.org/10.1111/bcp.13710

Nachnani, R., Knehans, A., Neighbors, J.D., Kocis, P.T., Lee, T., Tegeler, K., Trite, T., Raup-Konsavage, W.M., & Vrana, K.E. (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and cannabis. Frontiers in Pharmacology, 15, 1282831. https://doi.org/10.3389/fphar.2024.1282831

Nasrin, S., Watson, C.J.W., Perez-Paramo, Y.X., & Lazarus, P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metabolism and Disposition, 49(12), 1070–1080. https://doi.org/10.1124/dmd.121.000442

Page, R.L., Allen, L.A., Kloner, R.A., Carriker, C.R., Martel, C., Morris, A.A., Piano, M.R., Rana, J.S., & Saucedo, J.F. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation, 142(10), e131–e152. https://doi.org/10.1161/CIR.0000000000000883

Zanger, U.M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The information provided is not a substitute for professional medical advice. Always consult a qualified healthcare provider before making any decisions related to your health or medications. Never start, stop, or modify any medication without the guidance of your physician or pharmacist.